Update 04-01-2021: CTU offices are partly closed due to the COVID-19 pandemic until further notice. Some of CTU’s staff work at CTU, but we try at the same time to conduct as much work from our homes as possible. You can contact all of us by e-mail or by phone (see Contact).

Welcome to the Copenhagen Trial Unit − The CTU

The CTU is a clinical intervention research unit conducting clinical research within all specialties. We offer flexible collaboration and consulting at all stages of clinical research.

The CTU has been involved in the conduct of more than 151 randomised clinical trials in which more than 132,000 participants were randomised. We provide expertise and infrastructure in planning, conduct, analysis, and interpretation of randomised clinical trials, including development of trial methodology and education.

The CTU has been involved in the conduct of more than 500 protocols for systematic reviews, which has materialised in the publication of more than 300 systematic reviews published within and outside The Cochrane Collaboration. The CTU has developed methodology and software for conducting Trial Sequential Analysis (TSA). We provide advice, support, and full collaboration during the protocol and systematic review development. We offer expertise in search strategy design, conduct literature searches for systematic reviews, and offer help with or conduct of meta-analyses.

The CTU hosts the Editorial Team Office of the Cochrane Hepato-Biliary Group (CHBG) - one of the 56 global Collaborative Review Groups within The Cochrane Collaboration - as well as the Danish Clinical Research Infrastructures Network (DCRIN), the Danish coordinating hub of the Nordic Trial Alliance (NTA), and the Danish coordinating hub of the European Clinical Research Infrastructures Network (ECRIN).

We offer creative collaboration and consulting from concept,
through conduct and to completion.

News

Granholm A, Munch MW, Myatra SN, et al. Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol for a secondary bayesian analysis. Acta anaesthesiol Scand. 2021; 65:702–710. https://doi.org/10.1111/aas.1379
View here
Riberholt CG, Olsen MH, Søndergaard CB, et al. Early orthostatic exercise by head-up tilt with stepping vs. standard care after severe traumatic brain injury is feasible. Front. Neurol. 2021; 12:626014. doi: 10.3389/fneur.2021.626014 .
View here
Ovesen C, Jakobsen JC, Gluud C, et al. Tranexamic acid for prevention of hematoma expansion in intracerebral hemorrhage patients with or without spot sign. Stroke. 2021; (2629–2636). DOI: 10.1161/STROKEAHA.120.032426.
View here
Olsen MH, Hansen ML, Safi S, et al. Central data monitoring in the multicentre randomised SafeBoosC-III trial - a pragmatic approach. BMC Med Res Methodol. 2021 Jul 31; 21(1):160. doi: 10.1186/s12874-021-01344-4. PMID: 34332547; PMCID: PMC8325420.
View here
Nørskov AK, Lange T, Nielsen EE, et al. Assessment of assumptions of statistical analysis methods in randomised clinical trials: the what and how. BMJ evidence-based medicine 2021; 26:121–126.
View here
Dankiewicz J, Cronberg T, Lilja G, et al. Hypothermia versus normothermia after out-of-hospital cardiac arrest.
N Engl J Med. 2021 Jun 17;384(24):2283-2294. doi: 10.1056/NEJMoa2100591. PMID: 34133859.
View here
Petersen MW, Meyhoff TS, Helleberg M, et al. Low-dose hydrocortisone in patients with COVID-19 and severe hypoxia (COVID STEROID) trial-protocol and statistical analysis plan. Acta Anaesthesiol Scand. July 21, 2020;00:1–11.
View here
Storebø OJ, Gluud C. Methylphenidate for ADHD rejected from the WHO essential medicines list due to uncertainties in benefit-harm profile. BMJ Evidence-Based Medicine. April 24, 2020; Online ahead of print.
View here
Juul S, Gluud C, Simonsen S, et al. Blinding in randomised clinical trials of psychological interventions: a retrospective study of published trial reports. BMJ evidence-based medicine 2021; 26:109.
View here
Jakobsen JC, Wetterslev J, Gluud C. Considerations on the strengths and limitations of using disease-related mortality as an outcome in clinical research. BMJ evidence-based medicine 2021; 26:127–130.
View here